Xylazine Overdoses On the Rise


The increasing prevalence of fatal overdoses involving the veterinary sedative Xylazine, popularly known as the "Zombie Drug," is a pressing concern in Connecticut's drug market. Understanding the risks associated with Xylazine is crucial due to its potential severe health consequences. To delve deeper into this issue, watch the news clip below featuring our UNCAS Mobile Health Team addressing the Xylazine epidemic.

Narcan Resistance

It's vital to note that Xylazine exhibits resistance to Narcan, rendering the standard Narcan reversal procedure ineffective in case of an overdose.

About Xylazine

  • Nature and Usage

    Xylazine, classified as a veterinary tranquilizer by the National Institute on Drug Abuse (NIDA), lacks approval for human use.

  • Overdose Crisis Link

    Increasingly associated with overdose deaths in the ongoing drug addiction crisis, especially when combined with illicit fentanyl.

  • Patterns of Use

    Research indicates a trend of concurrent use with illicit fentanyl, knowingly or unknowingly, enhancing euphoric effects.

Nationwide Impact

  • Increased Deaths

    Statistics reveal a significant surge in overdose deaths involving Xylazine nationwide, particularly impacting the Northeast.

  • Regional Statistics

    Notably, Pennsylvania witnessed a drastic rise from 2% to 26% in drug overdose deaths involving Xylazine between 2015 and 2020.

  • Connecticut Impact

    In 2020, Xylazine contributed to 10% of drug overdose deaths in Connecticut.

Multi-Substance Involvement

  • Combination with Other Drugs

    Most fatalities linked to Xylazine and fentanyl also involved additional substances such as cocaine, heroin, benzodiazepines, alcohol, gabapentin, methadone, and prescription opioids.

Contact Information

For further inquiries about the Uncas Health District, interested parties can contact the Director of Health at (860) 823-1189.

Skip to content